A clinical challenge: the decontamination of microstructured surfaces
The treatment of peri-implantitis systematically faces a major obstacle: the incomplete elimination of biofilm on microstructured titanium surfaces. While mechanical debridement is the standard, its application alone often remains insufficient due to limited access to the implant threads and the morphology of the bone defects. In response to this observation, interest is focused on multimodal protocols integrating adjuvant technologies to optimize surface decontamination.
Study objectives and design
This prospective study, structured as an uncontrolled feasibility case series, evaluates the 12-month clinical outcomes of a standardized surgical protocol supplemented by the use of an alternating current device (Ximplant®). The primary objective is to report longitudinal changes in key periodontal parameters — probing depth (PD), bleeding on probing (BOP), plaque index, and suppuration — in six consecutive patients.
Feasibility assumptions
The study is based on the hypothesis that a combined approach, including surgical access, mechanical debridement, chemical conditioning, and electrical stimulation, achieves rapid and lasting clinical improvement. Given the study design where all components are applied simultaneously, the challenge is to validate the viability of this global protocol rather than isolating the specific efficacy of the alternating current device.
A multimodal protocol tested on a pilot cohort
This clinical study is a non-controlled prospective case series conducted on six patients (six implants). The objective? To evaluate the feasibility of a combined decontamination to treat peri-implantitis (PD ≥ 5 mm, bone loss ≥ 3 mm). Exclusion criteria were strict: presence of a pacemaker, pregnancy, or treatment of peri-implantitis within the last 6 months.
The surgical protocol followed a rigorous sequence for each case:
- Infectious phase: Systemic antibiotic therapy (Amoxicillin/Clavulanic Acid 750/250 mg, 2x/day for 8 days) started 48h before the procedure, combined with 0.2% chlorhexidine rinses.
- Surgical access: Full-thickness flap elevation, removal of granulation tissue (titanium/carbon curettes) and sonic debridement with PEEK inserts.
- Electro-chemical disinfection: Citric acid conditioning (30-60s) followed by the use of the Ximplant® device (alternating current, 625 kHz, 260 Vpp, 15 W) over four 3-second cycles separated by 2-second pauses.
- Longitudinal follow-up: Measurement of pocket depth (PD), bleeding on probing (BOP), plaque index (PI) and suppuration (SU) at baseline, then at 3 weeks, 6 months and 12 months.
Longitudinal variations were analyzed via repeated measures ANOVA. However, note the limitation of the exercise: with a sample size of n=6 and simultaneous application of therapies, this study does not allow for isolating the specific contribution of alternating current in the observed clinical resolution.
Significant clinical results from the third week
This prospective case series, involving six patients (six implants), highlights a rapid and lasting improvement in periodontal parameters following the application of the multimodal protocol combining mechanical debridement, chemical conditioning, systemic antibiotic therapy, and electrical stimulation via the Ximplant® device.
| Clinical Parameter (Mean ± SD) | Baseline | 3 weeks | 6 months | 12 months |
|---|---|---|---|---|
| Probing depth (PD) in mm | 4.56 ± 0.45 | 3.03 ± 0.44 | 3.08 ± 0.35 | 3.19 ± 0.41 |
| Bleeding on probing (BOP) | Present | Absent | Absent | Absent |
| Suppuration (SU) | Present | Absent | Absent | Absent |
Reduction in probing depth and stability at 12 months
The major result of this study lies in the drastic reduction of the mean probing depth (PD). Between the initial examination and the first follow-up at 3 weeks, the PD decreased from 4.56 ± 0.45 mm to 3.03 ± 0.44 mm. This improvement is statistically highly significant (p < 0.0001). For the practitioner, it is noteworthy that this clinical gain remains stable over time, with a PD measured at 3.19 ± 0.41 mm after one year of follow-up.
Eradication of inflammatory signs and plaque control
The impact of the protocol on clinical markers of infection is clear:
Pour vous équiper
Produits Delynov en lien avec cette thématique :
- x10 stylos à cautériser à usage unique HTC F7244 - FIAB (F7244) - Delynov (cautérisation haute température décontamination biofilm)
Delynov Chirurgie, votre fournisseur en surgical suture thread résorbables et non résorbables, consommables et instruments de chirurgie implantaire.
- BOP and Suppuration: Bleeding on probing and suppuration were completely absent on all implants during each follow-up visit (3 weeks, 6 months and 12 months).
- Plaque Index (PI): The authors report a marked improvement in local hygiene. Only one exception was noted: the buccal aspect of one implant showed a positive PI during the 3-week and 12-month follow-ups.
In concrete terms, these data indicate that the combined approach not only allows for effective short-term decontamination, but also promotes prolonged peri-implant tissue homeostasis, without recurrence of major inflammatory signs at one year.
Marked clinical efficacy over 12 months
The results of this case series suggest that a multimodal protocol, integrating surgical debridement and alternating current treatment, achieves a significant and stable reduction in probing depth (PD). Moving from an average of 4.56 mm to 3.19 mm over one year, while completely eliminating bleeding on probing (BOP) and suppuration (SU) on the six treated implants, is a strong indicator of short-term therapeutic success.
The "cocktail" effect: a deliberate methodological limitation
The main weakness of this study lies in its uncontrolled prospective design and its very small sample size (n=6). The authors state from the outset that it is impossible to isolate the specific contribution of the alternating current device compared to the other steps of the protocol (mechanical debridement, chemical conditioning, and systemic antibiotic therapy). This synergy of actions prevents drawing conclusions on the superiority of one technique over conventional methods, although the clinical response was rapid.
What are the prospects for the treatment of peri-implantitis?
Compared to classic literature data where mechanical debridement alone often struggles to decontaminate micro-structured surfaces, this combined approach seems to offer interesting tissue stability. Although the biophysical mechanisms are not analyzed here, the total disappearance of suppuration suggests an effective disruption of the complex biofilm. These results pave the way for larger-scale controlled clinical studies to validate the benefit of electrical stimulation as a complement to the classic surgical arsenal.
Summary of results
This series of clinical cases involving six implants demonstrates that a multimodal protocol combining surgical access, mechanical debridement, chemical conditioning, and an alternating current device significantly reduces the mean pocket depth, from 4.56 ± 0.45 mm to 3.19 ± 0.41 mm at 12 months (p < 0.0001). The authors report a total resolution of bleeding on probing and suppuration as early as the third week, results that remained stable throughout the one-year follow-up period.
In concrete terms, for the practitioner:
- Prioritize a multimodal approach: The success of decontamination relies on the combined action of mechanical, chemical, and electrical cleaning rather than on an isolated technique.
- Early and lasting stability: This protocol allows for rapid clinical improvement (visible from 3 weeks) that is maintained over time, offering interesting predictability for the stabilization of peri-implant tissues.
- Rigorous selection of defects: These results concern cases of peri-implantitis with bone loss ≥ 3 mm and partially preserved bone walls; the morphology of the defect remains a determining criterion for the success of the treatment.
Technical lexicon of the study
Ximplant®: Decontamination device delivering a high-frequency alternating current (625 kHz, 260 Vpp, 15 W). Its action is based on electrical stimulation aimed at reducing biofilm viability and weakening microbial adhesion on titanium.
Chemical conditioning: Protocol phase consisting of the local application of citric acid for 30 to 60 seconds on the implant surface, performed just before the electrical decontamination phase.
Sonic debridement: Use of a sonic handpiece equipped with PEEK (polyetheretherketone) inserts to mechanically disrupt the biofilm. The objective? To clean without altering the micro-topography of the implant surface.
Peri-implant defect: Morphological inclusion criterion defined in this series by a radiographic bone loss ≥ 3 mm associated with at least partially preserved bone walls, clinically verified during flap elevation.
Probing depth (PD): Clinical indicator of peri-implant health. Study measurements show a significant mean reduction from 4.56 ± 0.45 mm at baseline to stabilization at 3.19 ± 0.41 mm after 12 months.
Suppuration (SU): Clinical sign of active infection. In this case series, the disappearance of suppuration was noted in all patients from the 3-week follow-up and was maintained throughout the duration of the study.
Source
- Original title: Preliminary Clinical Outcomes of an Alternating-Current-Assisted Implant Surface Decontamination Protocol: A Prospective Case Series with 12-Month Follow-Up
- Authors: Dorian Kostandini, Antonella Mattei, Giovanni Falisi, Arianna Viarchi, Davide Gerardi, Angelo Bruni, Erda Qorri, Lía Hoz, Eduardo Basañes Rivera, Sofia Rastelli, Roberto Gatto, Marco Severino, Gianluca Botticelli
- Publication: Bioengineering - 2026-08-27
- DOI: https://doi.org/10.3390/bioengineering13090996
Also read in the Delynov blog
Nodirbek Karimqulov, Nurmuhammad Teshaboyev, Boburbek Jahongirov
Prevention of peri-implantitis: synergy between surface technologies and therapeutic protocols
Wenjie Zhou, Ausra Ramanauskaite, Clemens Raabe, Emilio A. Cafferata, Neelam Lingwal, Fra…, Open Access CRIS of the University of Bern
Peri-implantitis: key factors for successful surgical treatment
Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.



















